Hamakawa Takashi, Kojima Yoshiyuki, Naiki Taku, Kubota Yasue, Yasui Takahiro, Tozawa Keiichi, Hayashi Yutaro, Kohri Kenjiro
Department of Nephro-Urology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-chou, Mizuho-ku, Nagoya 467-8601, Japan.
Case Rep Urol. 2013;2013:915874. doi: 10.1155/2013/915874. Epub 2013 May 8.
Primary signet-ring cell carcinoma of the urinary bladder is extremely rare and patient survival is very poor. The disease usually presents at advanced stages because the cancer progresses rapidly. The only option for effective treatment is radical cystectomy, and no effective chemotherapy has been established for this variant. We report a case of signet-ring cell carcinoma of the urinary bladder with a long-term survival of 90 months owing to radical cystectomy and combination adjuvant chemotherapy with S-1 and cisplatin. To our knowledge, this is the first report to demonstrate the long-term therapeutic activity of combination S-1 and cisplatin adjuvant chemotherapy against invasive signet-ring cell carcinoma of the urinary bladder.
原发性膀胱印戒细胞癌极为罕见，患者生存率很低。该疾病通常在晚期出现，因为癌症进展迅速。有效治疗的唯一选择是根治性膀胱切除术，且尚未确立针对这种变体的有效化疗方案。我们报告一例膀胱印戒细胞癌患者，由于接受了根治性膀胱切除术以及S-1和顺铂联合辅助化疗，生存期长达90个月。据我们所知，这是首例证明S-1和顺铂联合辅助化疗对浸润性膀胱印戒细胞癌具有长期治疗活性的报告。
